Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Single Dose Navocaftor in Male CF Patients
NCT03589313Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navocaftor in cystic fibrosis (CF), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero until 24 hours post-dose and 1 more. Started Feb 2018; status: completed.
02
Drugs
navocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03589313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589313.